ATI-045

DRUG2 trials

Sponsors

Aclaris Therapeutics Inc., Aclaris Therapeutics, Inc.

Conditions

ADAtopicAtopic DermatitisAtopic dermatitisDermatitisEczema

Phase 2

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

Active, not recruitingNCT07011706

Aclaris Therapeutics, Inc.AD, Atopic, Atopic Dermatitis +2

Start: 2025-05-30End: 2026-10-01Updated: 2026-03-25

A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients with Moderate-to-Severe Atopic Dermatitis

WithdrawnCTIS2024-520302-19-00

Aclaris Therapeutics Inc.Atopic dermatitis

Target: 54Updated: 2025-09-08